Stock Track | Omeros Soars 5.14% After-Hours on Strong Q1 Profit Turnaround and YARTEMLEA Launch Progress

Stock Track05-14

Omeros Corporation's stock surged 5.14% in after-hours trading on Wednesday, following the release of its first-quarter financial results.

The biotech company reported a significant swing to a net income of $56.1 million, or $0.78 per share, for Q1 2026, compared to a net loss in the prior-year period. The results were driven by the initial U.S. commercial launch of its drug YARTEMLEA, which generated $9.9 million in net sales for the quarter. On an adjusted basis, the company's net loss narrowed to $0.24 per share, beating analyst estimates.

Investors also reacted positively to several forward-looking developments. The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, and recommended approval for a New Technology Add-On Payment. The company also completed a share repurchase and provided an outlook for regulatory decisions in Europe and clinical trial initiations later in the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172225932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 04:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172225932","market":"sg","top_or_hot":-1,"title":"Stock Track | Omeros Soars 5.14% After-Hours on Strong Q1 Profit Turnaround and YARTEMLEA Launch Progress","media":"Stock Track","content":"<p>Omeros Corporation's stock surged 5.14% in after-hours trading on Wednesday, following the release of its first-quarter financial results.</p><p>The biotech company reported a significant swing to a net income of $56.1 million, or $0.78 per share, for Q1 2026, compared to a net loss in the prior-year period. The results were driven by the initial U.S. commercial launch of its drug YARTEMLEA, which generated $9.9 million in net sales for the quarter. On an adjusted basis, the company's net loss narrowed to $0.24 per share, beating analyst estimates.</p><p>Investors also reacted positively to several forward-looking developments. The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, and recommended approval for a New Technology Add-On Payment. The company also completed a share repurchase and provided an outlook for regulatory decisions in Europe and clinical trial initiations later in the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omeros Soars 5.14% After-Hours on Strong Q1 Profit Turnaround and YARTEMLEA Launch Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omeros Soars 5.14% After-Hours on Strong Q1 Profit Turnaround and YARTEMLEA Launch Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 04:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Omeros Corporation's stock surged 5.14% in after-hours trading on Wednesday, following the release of its first-quarter financial results.</p><p>The biotech company reported a significant swing to a net income of $56.1 million, or $0.78 per share, for Q1 2026, compared to a net loss in the prior-year period. The results were driven by the initial U.S. commercial launch of its drug YARTEMLEA, which generated $9.9 million in net sales for the quarter. On an adjusted basis, the company's net loss narrowed to $0.24 per share, beating analyst estimates.</p><p>Investors also reacted positively to several forward-looking developments. The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, and recommended approval for a New Technology Add-On Payment. The company also completed a share repurchase and provided an outlook for regulatory decisions in Europe and clinical trial initiations later in the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMER","symbol_name":"奥麦罗制药","start_time":0,"source_url":"","article_id":"1172225932","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172225932","pubTimestamp":1778705105,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omeros Corporation's stock surged 5.14% in after-hours trading on Wednesday, following the release of its first-quarter financial results.The biotech company reported a significant swing to a net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMER":"奥麦罗制药"},"translate_title":"个股追踪|Omeros盘后飙升5.14%，因Q1盈利强劲扭亏为盈和YARTEMLEA上市进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1},"content_text":"Omeros Corporation's stock surged 5.14% in after-hours trading on Wednesday, following the release of its first-quarter financial results.The biotech company reported a significant swing to a net income of $56.1 million, or $0.78 per share, for Q1 2026, compared to a net loss in the prior-year period. The results were driven by the initial U.S. commercial launch of its drug YARTEMLEA, which generated $9.9 million in net sales for the quarter. On an adjusted basis, the company's net loss narrowed to $0.24 per share, beating analyst estimates.Investors also reacted positively to several forward-looking developments. The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, and recommended approval for a New Technology Add-On Payment. The company also completed a share repurchase and provided an outlook for regulatory decisions in Europe and clinical trial initiations later in the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172225932","isCrawlerRequest":true}